Chuanwen Wang

Chuanwen has advised on the following matters (including matters prior to his joining to Kirkland & Ellis):

• Edding Group Company Limited, an integrated biopharmaceutical company, in connection with a proposed merger and reverse takeover with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company
• Super Hi International Holding Ltd. (HKSE: 9658; NASDAQ: HDL) on its initial public offering on the Nasdaq Global Market, making it the first high-profile company to list first in Hong Kong and then in the United States in recent years
• The joint sponsors and underwriters on the global offering and listing of TUHU Car Inc. (HKSE: 9690) on the Main Board of HKEx. Tuhu is a leading online and offline integrated platform for automotive service in China
• The joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541) on the Main Board of HKEx. ImmuneOnco is a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China
• Super Hi International Holdings Ltd. (HKSE: 9658) on its listing by way of introduction on the Main Board of HKEx, which constituted a spin-off of Super Hi from the hotpot giant Haidilao International Holding Ltd. (HKSE: 6862) and its separate listing. Super Hi is a leading international Chinese restaurant brand
• The joint sponsors and underwriters on the global offering and listing of STAR CM Holdings Limited (HKSE: 6698) on the Main Board of HKEx. STAR CM is a leading variety program IP creator and operator in China
• The joint sponsors and underwriters on the US$1.52 billion global offering and dual primary listing of Li Auto Inc. (HKSE: 2015) on the Main Board of HKEx. LI Auto is a leading NEV automaker in China
• Suzhou Basecare Medical Corporate Limited (HKSE: 2170) on the US$233 million global offering of H-shares and listing on the Main Board of HKEx. Basecare is an innovative platform of genetic testing solutions for assisted reproduction in China
• MicroPort CardioFlow Medtech Corporation (HKSE: 2160), a medical device company in China focusing on the research, development, and commercialization of innovative transcatheter and surgical solutions for structural heart diseases, in connection with its:
  • US$322 million global offering and listing on the Main Board of HKEx. The listing is a spin-off from Hong Kong-listed MicroPort Scientific Corporation*; and
  • Pre-IPO round financing of approximately US$130 million*
• Haidilao International Holding Ltd (HKSE: 6862), a fast-growing Chinese cuisine restaurant brand focusing on hot pot cuisine, in connection with its:
  • US$964 million global offering and listing on the Main Board of HKEx*;
  • US$300 million follow-on financing by way of top-up placing; and
  • Landmark debut investment-grade offshore bond offering of US$600 million 2.150% notes due 2026*
• The joint sponsors and underwriters on the HK$975 million global offering and listing of Strawbear Entertainment Group (HKSE: 2125) on the Main Board of HKEx. Strawbear is a major drama series producer and distributor in China, covering the investment, development, production, and distribution of TV and web series*
• Alphamab Oncology (HKSE: 9966), a leading clinical-stage biopharmaceutical company in China, in connection with its:
  • US$234 million global offering and listing on the Main Board of HKEx*; and
  • US$60 million Series B financing led by Hudson Bay*
• The joint sponsors and underwriters on the US$397.4 million global offering and listing of Shanghai Henlius Biotech, Inc (HKSE: 2696) on the Main Board of HKEx. The listing is a dual-level spin-off from Hong Kong-listed Fosun International and A+H-listed Fosun Pharma. Shanghai Henlius Biotech, Inc. is a leading biopharmaceutical company in China*
• The joint sponsors and underwriters on the US$88 million global offering and listing of CANbridge Pharmaceuticals Inc. (HKSE: 1228) on the Main Board of HKEx. CANbridgePharmaceuticals is a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of biotech therapies
• Shandong Gold Mining Co., Ltd. (HKSE: 1787), an A-share listed company, in connection with its US$594 million global offering and listing of H-Shares on the Main Board of HKEx. Shandong Gold is engaged in the mining and smelting of gold*
• The joint sponsors and underwriters on the US$468 billion H-Share global offering and listing of Bank of Jiujiang Co., Ltd., (HKSE: 6190) on the Main Board of HKEx. Bank of Jiujiang is a leading regional commercial bank in China*
• The joint sponsors and underwriters on theUS$1 billion H-Share global offering and listing of Guangzhou Rural Commercial Bank Co., Ltd., (HKSE: 1551) on the Main Board of HKEx. Guangzhou Rural Commercial Bank is a leading rural commercial bank in China*
• The sole sponsor and underwriters on the US$198 million global offering and listing of China YuHua Education Corporation Limited on the Main Board of HKEx. Yuhua Education is a leading provider of private education from kindergarten to university in China*
• The sole sponsor and underwriters on the US$75.8 million global offering and listing of JNBY Design Limited (HKSE: 3306) on the Main Board of HKEx. JNBY Design is a designer brand fashion house in China*
• The joint sponsors and underwriters on the US$110.6 million global offering and listing of AsiaInfo Technologies Limited (HKSE: 1675) on the Main Board of HKEx. AsiaInfo Technologies Limited is a leading telecom software product and related service provider in China*
• The seller in connection with the placement of 14,500,000 existing shares of Alphamab Oncology (HKSE: 9966). The total transaction value is approximately HK$239.3 million*
• The sellers in connection with the placement of 47 million existing shares of Haidilao International Holding Ltd. (HKSE: 6862) The total transaction value is approximately HK$1.56 billion*
• MicroPort NeuroTech Limited (HKSE: 2172) in connection with its approximately US$31 million pre-IPO financing. MicroPort NeuroTech is a China-based company in the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients
• Represented listed companies and individuals under investigation by the Securities and Futures Commission for matters including allegations of market misconduct
• Advising the following companies on various post-listing compliance matters, including notifiable and connected transactions, equity and debt securities offering, capital reorganization, share incentive scheme and other Hong Kong Listing Rules and/or Takeovers Code related matters:
  • TUHU Car Inc.
  • Haidilao International Holding Ltd.
  • Alphamab Oncology
  • MicroPort CardioFlow Medtech Corporation
  • Suzhou Basecare Medical Corporate Limited
  • MicroPort Scientific Corporation*
  • China International Capital Corporation Limited*

*Experience prior to joining Kirkland & Ellis